Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple Turns 50: From Garage Startup to AI Crossroads 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
GAITHERSBURG, Md., Sept. 08, 2016 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in Washington, D.C. OpGen CEO Evan Jones will lead a presentation titled “Harnessing the power of informatics and genomic analysis to provide complete MDRO solutions” on Thursday, September 8 at 3:05 p.m. ET.
OpGen will also host a roundtable discussion called “Antibiotic resistant bacteria in our Integrated Healthcare Network: are new diagnostic tests needed?” on Friday, September 9 from 1:40 p.m. to 2:20 p.m. ET. The roundtable will feature Bert Lopansri, M.D., Associate Professor of Medicine, University of Utah; Chief of Infectious Diseases, Intermountain Healthcare; and Medical Director, Urban Central Region Microbiology Lab, Division of Infectious Diseases and Epidemiology.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen Michael Farmer Director, Marketing (240) 813-1284 [email protected] [email protected] Investor Relations LHA Kim Sutton Golodetz (212) 838-3777 [email protected] or Bruce Voss (310) 691-7100 [email protected] OpGen Media MacDougall Biomedical Communications Cammy Duong 781-235-3060 [email protected]
